The Management of Perforated Acute Appendicitis in Adult and Pediatric Populations

NCT ID: NCT04253899

Last Updated: 2023-04-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-20

Study Completion Date

2023-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients admitted at Marshall Health - Cabell Huntington Hospital with the diagnosis of acute perforated appendicitis or appendicular abscess larger than 3cm will be admitted and treated with percutaneous drainage and the IV antibiotics for 3 days. If the patient becomes afebrile and has a normal WBC, the patient will stay in the hospital for a single day with oral antibiotics and then will be discharged to continue oral antibiotics for seven more days. If the patient is febrile or has elevated WBC either after the 3 days of IV antibiotics or the single day of oral antibiotics, the patient will complete a course of IV antibiotics for a total of seven days. If still febrile, the patient will undergo further assessment.

A follow up will be conducted \~10 days after discharge from the hospital to determine if the patient is still symptomatic or asymptomatic. Asymptomatic patients will be followed up every month for 3 months, while symptomatic patients will be treated as needed. After 12 weeks, subjects will be randomized to interval appendectomy vs observation. Follow-ups will occur every 3 months for 12 months, when the study will be concluded.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Perforated Appendicitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard pediatric group:

patients ≤17 yo with acute perforated appendicitis and interval appendectomy (n=25)

Group Type ACTIVE_COMPARATOR

Appendectomy

Intervention Type PROCEDURE

Interval Appendectomy

Experimental pediatric group:

patients ≤17 yo with acute perforated appendicitis abscess and observation (n=25)

Group Type EXPERIMENTAL

Observation

Intervention Type OTHER

observation and follow up

Standard adult group:

patients ≥18 yo with acute perforated appendicitis and interval appendectomy (n=25)

Group Type ACTIVE_COMPARATOR

Appendectomy

Intervention Type PROCEDURE

Interval Appendectomy

Experimental adult group:

Patients ≥18 yo with acute perforated appendicitis and observation (n=25)

Group Type EXPERIMENTAL

Observation

Intervention Type OTHER

observation and follow up

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Appendectomy

Interval Appendectomy

Intervention Type PROCEDURE

Observation

observation and follow up

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women of all ages.
* Clinical and radiological diagnosis by contrast CT scan of acute perforated appendicitis.
* Formal consent for the present study must be signed by the patient or his/her parents
* Patients with initial presentation of a phlegmon (abscess in evolution)

Exclusion Criteria

* Patients with non-perforated appendicitis
* Presentation with initially non-perforated appendicitis but found perforation at surgery
* Patient with septic shock
* Patients who had previous appendectomy
* Current treatment of malignancy
* Immunocompromised patients
* Positive pregnancy test
* No consent for the study
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Marshall University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Juan Sanabria

Professor of Surgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Juan Sanabria, MD MSc FACS

Role: PRINCIPAL_INVESTIGATOR

Marshall University School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Marshall University School of Medicine

Huntington, West Virginia, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Juan Sanabria, MD MSc FACS

Role: CONTACT

216 647 8399

Michael Abdelmasseh, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Juan Sanabria, MD MSc FACS

Role: primary

216-647-8399

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1504002-3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

APPI-Cost Trial for Perforated Appendicitis
NCT06705842 RECRUITING PHASE4
Antibiotic Instillation in Appendicitis
NCT05470517 COMPLETED PHASE2